Arachidonic Acid-induced Platelet Aggregation Rate in Patients With Stable CAD Treated With Ticagrelor Monotherapy
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This study was a feasibility trial that was designed to provide preliminary observations and
generate hypotheses for future studies. The aim of the study is to estimate the difference of
arachidonic acid induced platelet aggregation rate between ticagrelor mono-therapy and
aspirin/ticagrelor dual-therapy after 14 days of treatment in patients with stable coronary
artery disease. The potential hypothesis is that the arachidonic acid (AA) induced platelet
aggregation rate after 2 weeks of ticagrelor mono-therapy is comparable to that of
aspirin/ticagrelor dual-therapy.